31 December 2021: Clinical Research
A Prospective Observational Study of 42 Patients with COVID-19 infection and a History of Hepatitis C Virus Infection and Thyroid Disease with Follow-Up Thyroid Function and Autoantibody Testing
Dumitru Cristinel Badiu 1B , Gabriel Cristian Popescu 1F , Anca Zgura 2A* , Adriana Mercan Stanciu 3F , Mihai Daniel Dodot 3F , Claudia Mehedintu 4C , Letitia Toma 3E , Simu Razvan 3B , Xenia Bacinschi 2D , Bogdan Haineala 5ADOI: 10.12659/MSM.935075
Med Sci Monit 2021; 27:e935075
Table 1 Baseline characteristics of the study group.
| Baseline characteristics | |
|---|---|
| Mean age | 52.67±21.08 years |
| Gender distribution | Female: 27 patients |
| Male: 15 patients | |
| Mean time-lapse after SVR | 14.6±7.2 months |
| Degree of liver fibrosis | F0–F2: 11 patients |
| F3: 19 patients | |
| F4: 12 patients | |
| Type of thyroid disease | Autoimmune thyroiditis: 37 patients |
| Hyperthyroidism: 2 patients | |
| Hypothyroidism: 5 patients | |
| ATPO (N | With autoimmune thyroiditis (37 patients): 982.1±426.6 |
| Without autoimmune thyroiditis (7 patients): 18.4±7.2 | |
| antiTG (N | With autoimmune thyroiditis (37 patients): 324.2±132.21 |
| Without autoimmune thyroiditis (7 patients): 65.9±21.7 | |
| TSH (N: 0.27–4.2μUI/mL) | Euthyroidism: 3.87±1.16 |
| Hypothyroidism (under levothyroxine): 2.14±0.81 | |
| Hyperthyroidism (under methimazole): 3.27±1.03 | |
| fT3 (N: 2.2–4.4 pg/ml) | Euthyroidism: 2.11±1.62 |
| Hypothyroidism (under levothyroxine): 3.91±0.62 | |
| Hyperthyroidism (under methimazole): 2.57±1.31 | |
| fT4 (N: 12–22 pmol/l) | Euthyroidism: 15.92±3.53 |
| Hypothyroidism (under levothyroxine): 18.13±6.22 | |
| Hyperthyroidism (under methimazole): 16.46±3.13 | |
| SVR – sustained virologic response after HCV infection. | |